| 前收盘价格 | 13.63 |
| 收盘价格 | 14.18 |
| 成交量 | 210,462 |
| 平均成交量 (3个月) | 183,750 |
| 市值 | 520,663,008 |
| 股市价格/股市净资产 (P/B) | 75.69 |
| 52周波幅 | |
| 利润日期 | 12 Aug 2025 - 18 Aug 2025 |
| 稀释每股收益 (EPS TTM) | -3.05 |
| 总债务/股东权益 (D/E MRQ) | 113.89% |
| 流动比率 (MRQ) | 6.61 |
| 营业现金流 (OCF TTM) | -102.25 M |
| 杠杆自由现金流 (LFCF TTM) | -62.83 M |
| 资产报酬率 (ROA TTM) | -39.04% |
| 股东权益报酬率 (ROE TTM) | -115.39% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Celcuity Inc. | 看涨 | 看涨 |
AIStockmoo 评分
2.8
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 2.75 |
|
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 13.21% |
| 机构持股比例 | 81.78% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 115.00 (Stifel, 736.36%) | 购买 |
| 中 | 93.50 (580.00%) | |
| 低 | 70.00 (Needham, 409.09%) | 购买 |
| 平均值 | 93.00 (576.36%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 68.74 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Stifel | 13 Nov 2025 | 115.00 (736.36%) | 购买 | 81.86 |
| HC Wainwright & Co. | 22 Oct 2025 | 77.00 (460.00%) | 购买 | 70.04 |
| 18 Aug 2025 | 66.00 (380.00%) | 购买 | 51.57 | |
| Needham | 20 Oct 2025 | 70.00 (409.09%) | 购买 | 70.58 |
| 03 Oct 2025 | 70.00 (409.09%) | 购买 | 50.51 | |
| Guggenheim | 22 Sep 2025 | 110.00 (700.00%) | 购买 | 52.49 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合